NDAORAL-28TABLET
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LO/OVRAL-28 is an oral contraceptive combination tablet containing ethinyl estradiol and norgestrel, indicated for pregnancy prevention in women of reproductive age. The progestin-estrogen combination works by suppressing ovulation, altering cervical mucus, and modifying the endometrium to prevent fertilization and implantation.
LOE Approaching
As LOE approaches, brand teams are focused on lifecycle management and transition planning; team size likely declining as resources shift to newer contraceptive products.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LO/OVRAL-28 offers limited growth trajectory given LOE status, but provides solid foundation in contraceptive market dynamics, lifecycle management, and defensive brand strategies. Professionals should view this role as a stepping stone to growth-stage therapeutic areas or specialty contraceptive segments.
Brand ManagerProduct Manager
Worked on LO/OVRAL-28 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.